Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of autosomal dominant Parkinson’s disease (PD) and have been associated with familial and sporadic PD. Reducing the kinase activity of LRRK2 is a promising therapeutic strategy since pathogenic mutations increase the kinase activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolz, Sarah Naomi, Salentin, Sebastian, Jennings, Gary, Haupt, V. Joachim, Sterneckert, Jared, Schroeder, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258795/
https://www.ncbi.nlm.nih.gov/pubmed/34285770
http://dx.doi.org/10.1016/j.csbj.2021.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258795/
https://www.ncbi.nlm.nih.gov/pubmed/34285770
http://dx.doi.org/10.1016/j.csbj.2021.06.013

Ejemplares similares